Correlation between obesity and ovarian cancer

Abstract

Li Xiahui, Zhang Xuemei, Jiang Kui. Correlation between obesity and ovarian cancer[J]. Journal of International Oncology, 2015, 42(2): 150-152.

［1］ Guo L, Li N, Wang G, et al. Body mass index and cancer incidence: a prospective cohort study in northern China［J］. Zhonghua Liu Xing Bing Xue Za Zhi, 2014, 35(3): 231-236. ［2］ Poorolajal J, Jenabi E, Masoumi SZ. Body mass index effects on risk of ovarian cancer: a metaanalysis［J］. Asian Pac J Cancer Prev, 2014, 15(18): 7665-7671. ［3］ Olsen CM, Nagle CM, Whiteman DC, et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium［J］. Endocr Relat Cancer, 2013, 20(2): 251-262. ［4］ Canchola AJ, Chang ET, Bernstein L, et al. Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort［J］. Cancer Causes Control, 2010, 21(12): 2241-2248. ［5］ De Stefano I, Zannoni GF, Prisco MG, et al. Cytoplasmic expression of estrogen receptor beta (ERbeta) predicts poor clinical outcome in advanced serous ovarian cancer［J］. Gynecol Oncol, 2011, 122(3): 573-579. ［6］ Lu Z, Zhang Y, Yan X, et al. Estrogen stimulates the invasion of ovarian cancer cells via activation of the PI3K/AKT pathway and regulation of its downstream targets Ecadherin and alphaactinin4［J］. Mol Med Rep, 2014, 10(5): 2433-2440. ［7］ Tas F, Karabulut S, Serilmez M, et al. Clinical significance of serum insulinlike growth factor1 (IGF1) and insulinlike growth factor binding protein3 (IGFBP3) in patients with epithelial ovarian cancer［J］. Tumour Biol, 2014, 35(4): 3125-3132. ［8］ Zhang Y, Daquinag AC, AmayaManzanares F, et al. Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment［J］. Cancer Res, 2012, 72(20): 5198-5208. ［9］ Chen C, Chang YC, Lan MS, et al. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways［J］. Int J Oncol, 2013, 42(3): 1113-1119. ［10］陈仲. 脂联素蛋白的纯化方法及卵巢癌ES2体外抑瘤活性研究［D］. 北京: 中国协和医科大学, 2007. ［11］ Dalamaga M. Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives［J］. Biomark Med, 2014, 8(1): 107-118. ［12］ Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth［J］. Nat Med, 2011, 17(11): 1498-1503. ［13］ Fotopoulou C, Richter R, Braicu EI, et al. Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking［J］. Ann Surg Oncol, 2011, 18(9): 2629-2637. ［14］ Worley MJ Jr, Guseh SH, RauhHain JA, et al. What is the optimal treatment for obese patients with advanced ovarian carcinoma?［J］. Am J Obstet Gynecol, 2014, 211(3): 231.e1-9. ［15］ Barrett SV, Paul J, Hay A, et al. Does body mass index affect progressionfree or overall survival in patients with ovarian cancer? Results from SCOTROC Ⅰ trial［J］. Ann Oncol, 2008, 19(5): 898-902. ［16］ Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study［J］. Gynecol Oncol, 2008, 109(3): 353-358. ［17］ AuYeung G, Webb PM, DeFazio A, et al. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)［J］. Gynecol Oncol, 2014, 133(1): 16-22. ［18］ Slaughter KN, Thai T, Penaroza S, et al. Measurements of adiposity as clinical biomarkers for firstline bevacizumabbased chemotherapy in epithelial ovarian cancer［J］. Gynecol Oncol, 2014, 133(1): 11-15.

[1]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[2]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[3]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[4]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.
[5]	Li Chenxi, Zhao Hongwei.Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors[J]. Journal of International Oncology, 2021, 48(3): 180-183.
[6]	Li Zhefeng, Li Jie, Zhao Xiaoting, Yue Wentao.GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway[J]. Journal of International Oncology, 2021, 48(12): 716-722.
[7]	Zheng Jing, Yao Sheng, Shen Wenjie, Sun Zhijia, Zhao Hui, Fu Yan, Gao Ke, Du Nan.Clinical study of intraperitoneal infusion of bevacizumab combined with albumin paclitaxel and carboplatin in carcinomatous peritoneal adhesion from ovarian cancer[J]. Journal of International Oncology, 2021, 48(11): 660-665.
[8]	Yang Lifen, Song Wei, Xu Dawei, Wu Jun, Gao Ran.Mechanisms of miR-103a-3p/CHI3L1 in proliferation and vascular mimicry of ovarian cancer cells[J]. Journal of International Oncology, 2020, 47(6): 333-339.
[9]	Xue Chen, Zhao Yue, Shi Guang, Tang Yan.Research progress of PD-1/PD-L1 inhibitors in ovarian cancer[J]. Journal of International Oncology, 2020, 47(5): 312-315.
[10]	Yang Yiting, Cheng Zhongping.The role of inflammatory cytokines in chemoresistance of epithelial ovarian cancer[J]. Journal of International Oncology, 2020, 47(4): 249-251.
[11]	Fan Yangyang, Wang Ying, Yuan Feng, Du Shanping, He Rongrong, Jia Yan.Study on the mechanism of MALAT1 targeting miR-142-3p in ovarian cancer chemotherapy resistance[J]. Journal of International Oncology, 2020, 47(2): 82-89.
[12]	Quan Ruiquan, Zhang Li, Kuang Li, Li Hongbo, Xiao Meixian.Efficacy of olaparib combined with bevacizumab in the treatment of patients with recurrent platinum-sensitive ovarian cancer and its effect on serum HE4, CA125 and CTC levels[J]. Journal of International Oncology, 2020, 47(10): 606-610.
[13]	Tang Nanmin, Yu Zhancai.Transforming growth factor-β signaling pathway and targeted therapy in ovarian cancer[J]. Journal of International Oncology, 2019, 46(9): 562-565.
[14]	Chu Chaonan, Huang Qi.Comparison of the efficacy and safety of liposome doxorubicin and gemcitabine combined with oxaliplatin in the treatment of recurrent platinum resistant ovarian cancer[J]. Journal of International Oncology, 2019, 46(1): 32-35.
[15]	Yuan Qiuyue, Qiao Huimin, Zhang Shengmiao, Xia Baoguo, Bi Shuna, Chen Long.Research progress of circulating tumor DNA in ovrian cancer[J]. Journal of International Oncology, 2019, 46(1): 57-60.

Correlation between obesity and ovarian cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments